Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate

C. James Chou, Thomas O'Hare, Sophie Lefebvre, David Alvarez, Jeffrey W. Tyner, Christopher A. Eide, Brian J. Druker, Joel M. Gottesfeld

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Chronic myeloid leukemia (CML) is characterized by the presence of a constitutively active Abl kinase, which is the product of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a selective inhibitor of the Bcr-Abl tyrosine kinase, has significantly improved the clinical outcome of patients with CML. However, subsets of patients lose their response to treatment through the emergence of imatinib-resistant cells, and imatinib treatment is less durable for patients with late stage CML. Although alternative Bcr-Abl tyrosine kinase inhibitors have been developed to overcome drug resistance, a cocktail therapy of different kinase inhibitors and additional chemotherapeutics may be needed for complete remission of CML in some cases. Chlorambucil has been used for treatment of B cell chronic lymphocytic leukemia, non-Hodgkin's and Hodgkin's disease. Here we report that a DNA sequence-specific pyrrole-imidazole polyamide-chlorambucil conjugate, 1R-Chl, causes growth arrest of cells harboring both unmutated BCR-ABL and three imatinib resistant strains. 1R-Chl also displays selective toxicities against activated lymphocytes and a high dose tolerance in a murine model.

Original languageEnglish (US)
Article numbere3593
JournalPloS one
Issue number10
StatePublished - Oct 31 2008

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate'. Together they form a unique fingerprint.

Cite this